Evaluation of the Ebola Vaccine's Acceptance Among Sub-Saharan African Communities: A Systematic Review and Meta-Analysis
By
Beni Matangi
Placide Matondo
Brandon Kayembe
Axel Okolo
Dieudonné Tawaba
Amede Kinuka
Donat Mangala
Ossam Odio
Nadine Mayasi
Tuna Lukiana
Madone Mandina
Taylor Pindi
Murielle Longokolo
Marcel Mbula
Hippolyte Situakibanza
Ben Bepouka
February 6, 2026
Clinical Scorecard: Evaluation of the Ebola Vaccine's Acceptance Among Sub-Saharan African Communities: A Systematic Review and Meta-Analysis
At a Glance
Category Detail
Condition Ebola Virus Disease (EVD) Key Mechanisms Transmission through direct contact with infected fluids; vaccination as a preventive measure. Target Population Individuals or communities residing in sub-Saharan Africa. Care Setting Public health and vaccination campaigns.
Key Highlights
EVD has a high case-fatality rate averaging around 50%. Vaccine hesitancy is a major barrier to achieving optimal vaccination coverage. Two vaccines are licensed for EVD prevention: Ad26.ZEBOV/MVA-BN-Filo and rVSVΔG-ZEBOV-GP. Determinants of vaccine acceptability include sociodemographic factors and trust in health authorities. Acceptability rates vary significantly across different studies and settings. Guideline-Based Recommendations
Diagnosis
Assess willingness to receive the Ebola vaccine through surveys. Management
Implement targeted interventions to improve vaccine acceptance. Monitoring & Follow-up
Track vaccination rates and public perception of vaccine safety and efficacy. Risks
Address misinformation and distrust that contribute to vaccine hesitancy. Patient & Prescribing Data
Sub-Saharan African communities at risk of EVD.
Vaccination is crucial for preventing EVD outbreaks.
Clinical Best Practices
Engage community leaders to build trust in vaccination efforts. Utilize the WHO's '3Cs' model to address vaccine hesitancy. Provide clear and accessible information about vaccine safety and efficacy. References
